Christian Behrenbruch net worth and biography

Christian Behrenbruch Biography and Net Worth

Dr Behrenbruch has over two decades of radiopharmaceuticals experience and a strong track record in global healthcare and biotechnology entrepreneurship and technology commercialisation. He brings a unique blend of technical expertise and executive leadership to guide Telix as it enters the next stage of its strategy.

Dr Behrenbruch has a strong focus on purpose and values-leadership and is well versed in all aspects of running a publicly listed company as both CEO and Director in the United States and Australia.

Dr Behrenbruch holds a DPhil (PhD) in biomedical engineering from the University of Oxford, an executive MBA jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor from the University of Melbourne. He is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors.

What is Christian Behrenbruch's net worth?: The estimated net worth of Christian Behrenbruch is at least $224.85 million as of April 29th, 2026. Behrenbruch owns 20,742,935 shares of Telix Pharmaceuticals stock worth more than $224,853,415 as of May 11th. This net worth evaluation does not reflect any other assets that Behrenbruch may own. Learn More about Christian Behrenbruch's net worth.
How do I contact Christian Behrenbruch?: The corporate mailing address for Behrenbruch and other Telix Pharmaceuticals executives is , , . Telix Pharmaceuticals can also be reached via phone at 61-3-9093-3855 and via email at [email protected]. Learn More on Christian Behrenbruch's contact information.
Has Christian Behrenbruch been buying or selling shares of Telix Pharmaceuticals?: In the last ninety days, Christian Behrenbruch has bought $996,738.45 in shares of Telix Pharmaceuticals stock. Most recently, on Wednesday, April 29th, Christian Behrenbruch bought 33,435 shares of Telix Pharmaceuticals stock. The stock was acquired at an average cost of $14.87 per share, with a total value of $497,178.45. Following the completion of the transaction, the chief executive officer now directly owns 20,742,935 shares of the company's stock, valued at $308,447,443.45. Learn More on Christian Behrenbruch's trading history.
Who are Telix Pharmaceuticals' active insiders?: Telix Pharmaceuticals' insider roster includes Christian Behrenbruch (CEO), and Christian Behrenbruch (CEO). Learn More on Telix Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Telix Pharmaceuticals?: In the last twelve months, Telix Pharmaceuticals insiders bought shares 2 times. They purchased a total of 67,935 shares worth more than $996,738.45. The most recent insider tranaction occured on April, 29th when CEO Christian Behrenbruch bought 33,435 shares worth more than $497,178.45. Learn More about insider trades at Telix Pharmaceuticals.
Information on this page was last updated on 4/29/2026.

Christian Behrenbruch Insider Trading History at Telix Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/29/2026	Buy	33,435	$14.87	$497,178.45	20,742,935
4/28/2026	Buy	34,500	$14.48	$499,560.00	20,709,500

Christian Behrenbruch Buying and Selling Activity at Telix Pharmaceuticals

Telix Pharmaceuticals Company Overview

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Today's Range

Now: $10.82

$10.72

$11.04

50 Day Range

MA: $9.18

$6.79

$11.24

2 Week Range

Now: $10.82

$6.28

$18.49

Volume

133,106 shs

Average Volume

229,619 shs

Market Capitalization

$3.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08